Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants.

Risk of breast cancer in association with exposure to two different groups of tricyclic antidepressants.
复制标题

乳腺癌风险与接触两组不同的三环类抗抑郁药有关。

DOI:
10.1002/pds.1233
复制
发表时间:
2006
影响因子:
2.6
通讯作者:
Collet,Jean-Paul
Collet,Jean-Paul
中科院分区:
医学4区
文献类型:
--
作者:
Tamim,Hani;Boivin,Jean-Francois;Hanley,James;Stang,Maryrose;Collet,Jean-Paul

文献摘要

相似文献

2002年,我们报道了一项流行病学研究,发现某些三环类抗抑郁药(在果蝇中被鉴定为具有遗传毒性)与乳腺癌风险增加有关,当暴露于诊断日期前11-15年时。结果发现的影响导致我们进行一个单独的病例对照研究,使用相同的源人口,以验证我们以前的研究得出的结论。29320名年龄和时间相匹配的对照者。结果暴露于遗传毒性TCA 11- 15之间的相关性,在诊断前15年,乳腺癌发展的风险要弱得多,与我们以前的研究报告相比。诊断前11-15年暴露于高剂量遗传毒性TCA的女性患乳腺癌的相对风险为1.17(95%CI:0.79-1.74),而在同一时期暴露于高水平非遗传毒性TCA的女性中,其为0.95(95%CI:0.61-1.48).结论总之,我们没有发现支持性证据表明在过去20年中暴露于TCA的女性患乳腺癌的风险增加。版权所有© 2006约翰威利父子有限公司。
PurposeIn 2002, we reported an epidemiological study in which we found that some tricyclic antidepressants (identified as genotoxic inDrosophila Melanogaster) were associated with an increased risk of breast cancer, when exposure took place 11–15 years before the date of diagnosis. The implications of the results found lead us to carry out a separate case‐control study, using the same source population, to validate the conclusions drawn from our previous study.MethodsWe accrued 7330 breast cancer cases, diagnosed between 1981 and 2000, and 29 320 controls matched on age and time.ResultsThe association between exposure to genotoxic TCAs 11–15 years before diagnosis and the risk of breast cancer development was much weaker, as compared to what was reported in our previous study. The relative risk of breast cancer in women exposed to high doses of genotoxic TCAs 11–15 years before diagnosis was 1.17 (95%CI: 0.79–1.74), while in women exposed to high levels of non‐genotoxic TCAs during the same period it was 0.95 (95%CI: 0.61–1.48).ConclusionIn conclusion, we did not find supporting evidence for an increased risk of breast cancer among women exposed to TCAs up to 20 years in the past. Copyright © 2006 John Wiley & Sons, Ltd.